[Treatment outcome of peptide vaccination for advanced colorectal cancer].

Abstract

Complementary DNA( cDNA) microarray technology coupled with laser microdissection has been used to identify human leukocyte antigen (HLA)-A24-restricted epitope peptides as potential targets for cancer vaccination in colorectal cancer patients. These antigenic peptides were derived from 2 different cancer-testis antigens, ring finger protein 43 (RNF43) and translocase of outer mitochondrial membrane 34( TOMM34). We conducted a clinical trial of colorectal cancer-specific peptide( RNF43, TOMM34) vaccines with uracil/tegafur( UFT)+Leucovorin( LV) for the treatment of advanced or recurrent colorectal cancer. The vaccinations were well tolerated without any serious adverse events. There were long-term survivors in the group showing cytotoxic T lymphocyte (CTL) responses against both RNF43 and TOMM34, as well as in the group showing CTL responses against either RNF43 or TOMM34. A new study has been planned to obtain more immunological responses. We started a clinical trial of vaccines against multiple peptides (RNF43, TOMM34, forkhead box protein M1 [FOXM1], maternal embryonic leucine zipper kinase [MELK], holliday junction recognition protein[HJURP], vascular endothelial growth factor receptor 1[VEGFR1], and VEGFR2) for the treatment of advanced or recurrent colorectal cancer.

• Authors: Fumiaki Sugiura, Keisuke Inoue, Akihiro Kogita, Yasumasa Yoshioka, Jinichi Hida, Kiyotaka Okuno, Yasushi Sukegawa
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 40 Issue 12 Pg. 1584-6 (Nov 2013) ISSN: 0385-0684 [Print] Japan
• PMID: 24393856 (Publication Type: Controlled Clinical Trial, English Abstract, Journal Article)

Chemical References

• Cancer Vaccines
• Vaccines, Subunit
• Tegafur
• Uracil
• Leucovorin

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (administration & dosage, therapeutic use)
• Cancer Vaccines (immunology, therapeutic use)
• Colorectal Neoplasms (drug therapy, immunology, pathology)
• Female
• Humans
• Leucovorin (administration & dosage)
• Male
• Middle Aged
• Neoplasm Staging
• Tegafur (administration & dosage)
• Treatment Outcome
• Uracil (administration & dosage)
• Vaccines, Subunit (immunology, therapeutic use)